ARTICLE SUMMARY:
New device-based interventions for AAA may offer an alternative to prolonged surveillance in treating abdominal aortic aneurysms. Excerpted from our recent MTS feature, "Living Under Surveillance: Can New AAA Treatments Change the Story?"
An abdominal aortic aneurysm (AAA) is one of the more unsettling diagnoses in vascular medicine: a weakened and gradually enlarging segment of the body’s largest artery that may remain silent for years before suddenly rupturing with catastrophic consequences. Yet despite the potentially fatal nature of rupture, most small AAAs are not immediately repaired. Current clinical practice generally reserves surgical or endovascular intervention for aneurysms that exceed established diameter thresholds—typically around 5.5 cm—or demonstrate rapid expansion. Until then, patients are usually managed with aggressive cardiovascular risk reduction, including smoking cessation, blood pressure and lipid control, and regular imaging surveillance. Monitoring intervals vary by aneurysm size, ranging from every two to three years for smaller aneurysms to every three to six months as they approach the threshold for repair.
This strategy of “watchful waiting” is grounded in evidence showing that early intervention (surgical or endovascular repair) on small aneurysms has not consistently improved survival outcomes compared with surveillance alone. But for many patients, living with an aneurysm under observation can be psychologically burdensome, shaped by the awareness that rupture is frequently sudden and often fatal. The limitations of diameter-based management are also increasingly apparent.
Women, for example, are known to experience AAA rupture at smaller vessel diameters than men, raising concerns that current treatment thresholds may underestimate risk in certain populations. The WARRIORS trial investigators are out to understand this disparity, according to a recent presentation at the Charing Cross Symposium. WARRIORS aims to enroll 1,112 women aged 50 and over with aneurysms of 4–5.5 cm in diameter to determine if, in women with smaller AAAs, early repair using EVAR (endovascular aneurysm repair) compared to the standard of surveillance and repair, will reduce the incidence of AAA rupture and aneurysm-related mortality at five years.
In this context, the emergence of new device-based interventions aimed at treating AAAs earlier in their course could represent a significant shift in how clinicians approach aneurysm management—potentially offering an alternative to prolonged surveillance before the danger becomes acute.
This is the goal of Nectero Therapeutics, the first company to target smaller aneurysms with a minimally invasive catheter-based approach. Its Nectero EAST (Endovascular Aneurysm Stabilization Treatment) System uses a dual-balloon catheter to deliver a drug (pentagalloyl glucose) into the aneurysm wall. The drug binds to elastin and collagen in the aortic wall to strengthen it. In light of the great unmet clinical need, the company has received both FDA Fast Track and Breakthrough Device designation.
In April 2026 at the Charing Cross conference, Nectero’s lead investigator, Andrew Holden, MD, presented promising two-year first-in-human results, showing safety and efficacy in the treatment of small to medium-sized infrarenal AAAs in the diameter range of 3.5-5 cm. For 46 patients with an average age of 70, 89% of them male with an average BMI of 27 kg/m2 (overweight), there was 100% technical success, no major adverse events through 30 days, and no treatment-related adverse events after 30 days. Through two-year follow-up, investigators measured a median aneurysm diameter growth of 1 mm per year, with 90% of aneurysms growing less than expected compared to historically documented growth rates. AAA proximal neck diameters also remained stable.
Strategic companies are obviously keen to have a solution to offer patients and their treating physicians for this underserved condition, which results in 15,000 deaths each year. Boston Scientific, for one, led Nectero’s $19.5 million Series C round, and participated in its $96 million Series D.
At least one more solution is coming, according to a presentation at the recent MedTech Strategist Innovation Summit in Dublin. Early-stage Angiolutions hopes to offer the first mechanobiological treatment for AAAs, to arrest their development at earlier stages.
Continue reading here.